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Background: Differences in drug-eluting stents (DES) platforms may impact the long-term safety and efficacy outcomes of ‘all comers’ coronary pts 
treated for extended clinical and angiographic indications. We thus aimed to ascertain the long-term clinical outcomes using various DES in routine 
clinical practice at our institution.
Methods: We analyzed a comprehensive registry of 7,662 pts undergoing PCI of whom 3,047 were treated using DES and 4,615 pts had BMS. 
Propensity score was used for stratified analysis of outcomes and for matching between each DES vs. it corresponding BMS group. Outcomes were 
total mortality, MI, death/MI, TVR and composite MACE (death/MI/TVR).
Results: Pts in the DES group were more likely to be diabetic and had use of longer or more stents, treatment of more lesions and of more 
proximal vessels. Follow-up time was 3 years. Outcomes of each DES vs. BMS treatment using propensity score matching is shown in the Table:
Conclusions: Our DES-specific and risk-adjusted analysis indicated that: 1) DES may vary in their long-term clinical outcomes vs. BMS, 2) SES and 
EES had the most profound MACE and mortality benefits compared with BMS.
DES vs. BMS clinical outcomes analysis (3 years) *P<0.01
SES vs. BMS PES vs. BMS ZES vs. BMS EES vs. BMS
Matched pts (N) 1389 vs. 1389 345 vs. 345 464 vs. 464 369 vs. 369
Death (%) 5.8 vs. 11.0* 5.4 vs. 9.7 12.4 vs. 11.8 2.5 vs. 9.5*
Death/MI (%) 7.6 vs. 14.3* 6.3 vs. 11.6* 14.6 vs. 14.2 3.6 vs. 10.6*
TVR (%) 7.0 vs. 10.4* 6.7 vs. 8.0 7.4 vs. 13.2* 5.4 vs. 6.7
MACE (%) 12.9 vs. 22.6* 13.1 vs. 17.8 20.4 vs. 24.9 8.2 vs. 16.6*
